Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

Conditions

• Cytomegalovirus Infections

Interventions

• BIOLOGICAL: V160 Low Dose IM
• BIOLOGICAL: V160 Medium Dose IM
• BIOLOGICAL: V160 High Dose IM
• BIOLOGICAL: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM
• BIOLOGICAL: V160 High Dose plus MAPA 225 µg /dose IM
• BIOLOGICAL: V160 Maximum Dose IM
• OTHER: Placebo IM
• BIOLOGICAL: V160 Medium Dose ID
• OTHER: Placebo ID

Sponsor

Merck Sharp & Dohme LLC